Stuart Therapeutics Reports First Patient, First Visit in the P-III Study of Vezocolmitide for Treating Dry Eye Disease
Shots:
- Stuart Therapeutics has reported First Patient First Visit (FPFV) for the company's P-III clinical study of vezocolmitide (ST-100) for the treatment of patients with Dry Eye Disease
- The P-III trial evaluates the safety, efficacy and a single dose level of vezocolmitide ophthalmic solution vs PBO in patients with Dry Eye Disease. The company anticipates recruitment of 320 individuals in the study
- Vezocolmitide is based on the company's patented synthesized polypeptide collagen mimetic peptide platform, PolyCol
Ref: PR Newswire | Image: Stuart Therapeutics
Related News:- Stuart Therapeutics Entered into an Exclusive License Agreement with Glaukos Corporation to Develop the First Neuroprotective Therapy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
